Rezolute, Inc. Files 8-K with Financials and Exhibits
Ticker: RZLT · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1509261
| Field | Detail |
|---|---|
| Company | Rezolute, Inc. (RZLT) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
Rezolute filed an 8-K on 9/9/24 - check financials and exhibits.
AI Summary
Rezolute, Inc. filed an 8-K on September 9, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and headquartered in Redwood City, California.
Why It Matters
This filing provides important updates and financial information for investors and stakeholders of Rezolute, Inc.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Rezolute, Inc. (company) — Registrant
- AntriaBio, Inc. (company) — Former company name
- September 9, 2024 (date) — Filing date
- 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Rezolute, Inc.?
The primary purpose is to provide a Regulation FD Disclosure and to file Financial Statements and Exhibits, as reported on September 9, 2024.
When was Rezolute, Inc. previously known by another name?
Rezolute, Inc. was formerly known as AntriaBio, Inc., with a name change date of January 14, 2013.
Where are Rezolute, Inc.'s principal executive offices located?
Rezolute, Inc.'s principal executive offices are located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065.
What is Rezolute, Inc.'s state of incorporation?
Rezolute, Inc. is incorporated in Nevada.
What is the SIC code for Rezolute, Inc.?
The Standard Industrial Classification (SIC) code for Rezolute, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-09 07:30:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
Filing Documents
- tm2420844d2_8k.htm (8-K) — 26KB
- tm2420844d2_ex99-1.htm (EX-99.1) — 12KB
- tm2420844d2_ex99-1img001.jpg (GRAPHIC) — 12KB
- 0001104659-24-097969.txt ( ) — 229KB
- rzlt-20240909.xsd (EX-101.SCH) — 3KB
- rzlt-20240909_lab.xml (EX-101.LAB) — 33KB
- rzlt-20240909_pre.xml (EX-101.PRE) — 22KB
- tm2420844d2_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On September 9, 2024, Rezolute, Inc. issued a press release to announce that the U.S. Food and Drug Administration has completely removed the partial clinical holds on RZ358 (ersodetug) for the treatment of hypoglycemia as a result of congenital hyperinsulinism. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated September 9, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: September 9, 2024 By: /s/Nevan Charles Elam Nevan Charles Elam Chief Executive Officer